- Home
- RBC vs GMAB Comparison
RBC vs GMAB Comparison
Compare RBC & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBC
- GMAB
- Stock Information
- Founded
- RBC 1919
- GMAB 1999
- Country
- RBC United States
- GMAB Denmark
- Employees
- RBC N/A
- GMAB N/A
- Industry
- RBC Metal Fabrications
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RBC Industrials
- GMAB Health Care
- Exchange
- RBC Nasdaq
- GMAB Nasdaq
- Market Cap
- RBC 10.4B
- GMAB 12.1B
- IPO Year
- RBC 2005
- GMAB N/A
- Fundamental
- Price
- RBC $357.15
- GMAB $22.34
- Analyst Decision
- RBC Buy
- GMAB Buy
- Analyst Count
- RBC 8
- GMAB 9
- Target Price
- RBC $363.50
- GMAB $40.71
- AVG Volume (30 Days)
- RBC 173.9K
- GMAB 1.9M
- Earning Date
- RBC 01-31-2025
- GMAB 02-12-2025
- Dividend Yield
- RBC N/A
- GMAB N/A
- EPS Growth
- RBC 22.03
- GMAB 83.82
- EPS
- RBC 7.30
- GMAB 16.85
- Revenue
- RBC $1,612,300,000.00
- GMAB $2,988,286,182.00
- Revenue This Year
- RBC $6.07
- GMAB $18.78
- Revenue Next Year
- RBC $7.73
- GMAB $14.98
- P/E Ratio
- RBC $48.94
- GMAB $12.94
- Revenue Growth
- RBC 4.63
- GMAB 30.67
- 52 Week Low
- RBC $241.43
- GMAB $18.64
- 52 Week High
- RBC $372.83
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- RBC 58.61
- GMAB 65.39
- Support Level
- RBC $361.35
- GMAB $18.74
- Resistance Level
- RBC $372.83
- GMAB $22.55
- Average True Range (ATR)
- RBC 8.99
- GMAB 0.46
- MACD
- RBC -0.68
- GMAB 0.39
- Stochastic Oscillator
- RBC 42.90
- GMAB 94.64
About RBC RBC Bearings Incorporated
RBC Bearings Inc is an international manufacturer and marketer of highly engineered precision bearings, components and essential systems for the industrial, defense and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The end market is the United States of America. The company has two reportable segments: Aerospace Defense segment represents the end markets for the company's highly engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and Industrial segment represents the end markets for the company's engineered bearings and precision components used in various industrial applications. It derives maximum revenue from Industrial Segment.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.